ARUN PATEL: HYPERTENSION AND TYPE 2 DIABETES —
SHADOW HEALTH MEDICATION SELECTION
CORE DOMAINS
Case Overview and Patient Demographics
Assessment and Diagnostic Findings
Pharmacological Management: Antihypertensive Selection
Pharmacological Management: Antidiabetic Selection
Patient Education and Lifestyle Modifications
Integrated Clinical Reasoning
INTRODUCTION
This comprehensive medication selection guide is designed for nursing and
advanced practice students completing the Shadow Health Digital Clinical
Experience (DCE) Assignment 10.2: Focused Exam — Hypertension and
Type 2 Diabetes (Arun Patel). It presents original, clinically reasoned
questions with detailed rationales aligned with the latest AHA/ACC
Hypertension Guidelines and ADA Standards of Care. Emphasis is placed
on evidence-based pharmacological decision-making, cost-conscious
prescribing, and patient-centered care planning. This resource prepares
candidates for the Shadow Health assignment and strengthens real-world
clinical judgment.
SECTION ONE: QUESTIONS 1–25
1. Arun Patel is a 38-year-old Indian American male who is 5'9" and
weighs 233 lbs. Based on these measurements, what is his BMI
classification?
A. Overweight
B. Normal weight
C. Obese (Class I)
D. Underweight
C. Obese (Class I)
RATIONALE: Arun's BMI is 34.4 kg/m², calculated as 233 lbs × 703 ÷
, 69 in², which places him in Obesity Class I (30.0–34.9 kg/m²). This elevated
BMI significantly increases his cardiovascular and metabolic risk,
contributing to his poorly controlled hypertension and type 2 diabetes.
South Asian populations exhibit a "thin-fat" phenotype characterized by
greater visceral adiposity, higher insulin resistance, and dyslipidemia at
lower BMI values compared to White and Black populations.
2. What is the significance of Arun Patel's South Asian ethnicity in
relation to his cardiovascular risk?
A. South Asian patients store excess adiposity preferentially in
subcutaneous hip and thigh tissue, which is metabolically protective
B. South Asian patients develop visceral adiposity and insulin resistance at
lower BMI thresholds, increasing metabolic and cardiovascular risk
C. South Asian patients have genetically elevated HDL cholesterol levels
that paradoxically increase atherosclerosis
D. South Asian patients are at lower risk for type 2 diabetes and
hypertension compared to other ethnic groups
B. South Asian patients develop visceral adiposity and insulin
resistance at lower BMI thresholds, increasing metabolic and
cardiovascular risk
RATIONALE: South Asian populations exhibit a "thin-fat" phenotype
characterized by greater visceral adiposity, higher insulin resistance, and
dyslipidemia at lower BMI values. This means cardiovascular and
metabolic risk begins at lower BMI thresholds than in White or Black
populations.
3. Which of the following best describes Arun's current medication
regimen before any adjustments?
A. Hydrochlorothiazide 50 mg PO daily, Metformin 850 mg PO TID,
Escitalopram 20 mg PO daily
B. Lisinopril 20 mg PO daily, Glipizide 5 mg PO daily, Sertraline 50 mg PO
daily
C. Amlodipine 10 mg PO daily, Metformin 500 mg PO BID, Fluoxetine 20
mg PO daily
SHADOW HEALTH MEDICATION SELECTION
CORE DOMAINS
Case Overview and Patient Demographics
Assessment and Diagnostic Findings
Pharmacological Management: Antihypertensive Selection
Pharmacological Management: Antidiabetic Selection
Patient Education and Lifestyle Modifications
Integrated Clinical Reasoning
INTRODUCTION
This comprehensive medication selection guide is designed for nursing and
advanced practice students completing the Shadow Health Digital Clinical
Experience (DCE) Assignment 10.2: Focused Exam — Hypertension and
Type 2 Diabetes (Arun Patel). It presents original, clinically reasoned
questions with detailed rationales aligned with the latest AHA/ACC
Hypertension Guidelines and ADA Standards of Care. Emphasis is placed
on evidence-based pharmacological decision-making, cost-conscious
prescribing, and patient-centered care planning. This resource prepares
candidates for the Shadow Health assignment and strengthens real-world
clinical judgment.
SECTION ONE: QUESTIONS 1–25
1. Arun Patel is a 38-year-old Indian American male who is 5'9" and
weighs 233 lbs. Based on these measurements, what is his BMI
classification?
A. Overweight
B. Normal weight
C. Obese (Class I)
D. Underweight
C. Obese (Class I)
RATIONALE: Arun's BMI is 34.4 kg/m², calculated as 233 lbs × 703 ÷
, 69 in², which places him in Obesity Class I (30.0–34.9 kg/m²). This elevated
BMI significantly increases his cardiovascular and metabolic risk,
contributing to his poorly controlled hypertension and type 2 diabetes.
South Asian populations exhibit a "thin-fat" phenotype characterized by
greater visceral adiposity, higher insulin resistance, and dyslipidemia at
lower BMI values compared to White and Black populations.
2. What is the significance of Arun Patel's South Asian ethnicity in
relation to his cardiovascular risk?
A. South Asian patients store excess adiposity preferentially in
subcutaneous hip and thigh tissue, which is metabolically protective
B. South Asian patients develop visceral adiposity and insulin resistance at
lower BMI thresholds, increasing metabolic and cardiovascular risk
C. South Asian patients have genetically elevated HDL cholesterol levels
that paradoxically increase atherosclerosis
D. South Asian patients are at lower risk for type 2 diabetes and
hypertension compared to other ethnic groups
B. South Asian patients develop visceral adiposity and insulin
resistance at lower BMI thresholds, increasing metabolic and
cardiovascular risk
RATIONALE: South Asian populations exhibit a "thin-fat" phenotype
characterized by greater visceral adiposity, higher insulin resistance, and
dyslipidemia at lower BMI values. This means cardiovascular and
metabolic risk begins at lower BMI thresholds than in White or Black
populations.
3. Which of the following best describes Arun's current medication
regimen before any adjustments?
A. Hydrochlorothiazide 50 mg PO daily, Metformin 850 mg PO TID,
Escitalopram 20 mg PO daily
B. Lisinopril 20 mg PO daily, Glipizide 5 mg PO daily, Sertraline 50 mg PO
daily
C. Amlodipine 10 mg PO daily, Metformin 500 mg PO BID, Fluoxetine 20
mg PO daily
